This author has not written his bio yet.
But we are proud to say that san1Admn contributed 199 entries already.
The Munich-based company GNA Biosolutions, which was already supported by SANEMUS AG in the Series C financing round in August 2019, has developed a particularly rapid Covid-19 test, which is to be launched on the market in June at the latest. The GNA Covid-19 system will consist of a portable testing device which can detect […]
The theme for 11th October 2019 is “Corporate Governance – Who controls the supervisory board?“ Ideas and inspiration will be provided by Daniela Bergdolt, Vice President of Deutsche Schutzvereinigung für Wertpapierbesitz e.V., Düsseldorf, and Prälat Dr. Lorenz Wolf, Chairman of the Chairman’s Conference of the Boards (Supervisory Board) of ARD, Munich. In addition, Dr. Joachim […]
The SANEMUS team has successfully supported the German Diagnostics Start-up GNA Biosolutions GmbH in its series C financing round. In the end 13.5 M$ were raised from well-known investors. Further information can be found in the press release
SANEMUS supports a biotech start-up in fundraising. The start-up focusses on diabetic complications and is currently developing the first causal, anti-infalmmatory treatment of diabetic nephropathy. If you are interested in an investment, please contact us.
Dr. Michael Thiel publishes Part III of the three-part series on venture capital in the German life-science-industry for the journal pharmind. The focus is on the consideration of institutional venture-capital-funds, which are the largest and most important investors for life science start-ups. An overview of selected European and German life science venture-capital-funds should clarify the […]
Dr. Michael Thiel published the second part of the three-part series on venture capital in the German life-science-industry. The article focuses on the role of life-science-corporate-venture-fonds for the innovation strategy of pharma and biotechnology companies. Moreover the motivation of corporate-venture-fonds for their investments and the differences in contrast to institutional venture-capital-fonds are discussed. You can […]
SANEMUS supports a German biotech start-up in searching venture capital. With its innovative, patented compound, the company offers a completely new therapeutic approach for the treatment of HIV patients who are resistant to therapy. Initial talks with institutional VCs have already been started. If you are interested in participating, please contact us.
SANEMUS supports a telemedicine start-up in fundraising. The start-up has developed a telemedicine system for the adjustment of medication of Parkinson’s Disease patients at home. After a successful test phase in inpatient and outpatient care, the market launch of the system in Germany is scheduled for autumn 2018. First talks with potential investors are being held. If you […]
SANEMUS has a new board of directors. Chairman is Dr. Theo Trucksaess assisted by Dr. Dr. Michael Dahm and Bernd Seibel. Dr. Theo Trucksaess is European Partner of Shentou Investment Co. Ltd. Dr. Dr. Michael Dahm is CMO of ORYX GmbH & Co. KG. Bernd Seibel, former General Partner at TVM, is investing as Business Angel in different Life Science […]
In the cover story of the latest issue of Life Sciences Platform, “Biotechnology 2017”, Dr. Thiel gives an overview of the development of the life science industry in the current year. Many doubts were raised trough electioneering in the US in 2016, but meanwhile the optimism in the growth of the life science market is […]
SANEMUS AG
Mannhardtstraße 6
80538 München
T +49 (0)171 60 32 076
info(at)sanemus(dot)com